The Center for New Revenue is delighted to announce that Dale Gieringer, Ph.D., long-time head of California NORML and a veteran cannabis policy scholar, has agreed to join its Board of Advisors.
I first became familiar with Dale’s work at the beginning of my work in marijuana tax policy. My first marijuana article, in State Tax Notes in 2011, cited his 1994 ‘Economics of Cannabis Legalization.’’ So he’s been at it a lot longer than I have, and longer than just about everyone else these days. When I went to California as part of the Newsom Blue Ribbon Commission studying legalization, I asked the late Mark Kleiman, a preeminent public policy scholar, whom I should listen to. Dale’s name was at the top of Mark’s list. I thought it would be.
Here’s a bio:
Dr. Dale Gieringer received his Ph.D at Stanford on the topic of DEA drug regulation. He is the author of articles on marijuana and driving safety, drug testing, marijuana health mythology, the economics of marijuana legalization, and DEA “drug enforcement abuse.” He is a co-author of Marijuana Medical Handbook: Practical Guide to Therapeutic Uses of Marijuana.
Dr. Gieringer has been the state coordinator of California NORML since 1987. He is also director of the California Drug Policy Forum (DPFCA) and treasurer of the Oakland Civil Liberties Alliance.
Dr. Gieringer has published research on medical marijuana usage, marijuana smoke harm reduction, potency testing, marijuana and driving safety, and drug urinalysis. He has testified before the legislature and in court on issues concerning personal use of marijuana. He was one of the original co-authors of California’s medical marijuana initiative, Prop. 215, and the proponent of Oakland’s Measure Z cannabis initiative in 2004.
In 2010, Dale was named High Times Freedom Fighter of the Year and in 2011 he received a Drug Policy Alliance Robert Randall Award for Citizen Action.
Dale and I don’t agree about everything, but that’s what a Board of Advisors is for. I will appreciate my friend’s counsel.
Pat Oglesby, Founder, Center for New Revenue, January 2, 2021